D.E. Shaw & Co
CLDX icon

D.E. Shaw & Co’s Celldex Therapeutics CLDX Stock Holding History

D.E. Shaw & Co’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.68M Sell
52,860
-83,464
-61% -$2.28M ﹤0.01% 3048
2025
Q4 		$3.7M Sell
136,324
-121,008
-47% -$3.19M ﹤0.01% 2557
2025
Q3 		$6.66M Sell
257,332
-388,325
-60% -$9M ﹤0.01% 1978
2025
Q2 		$13.1M Buy
645,657
+239,496
+59% +$4.66M 0.01% 1293
2025
Q1 		$7.37M Sell
406,161
-112,179
-22% -$2.51M 0.01% 1621
2024
Q4 		$13.1M Sell
518,340
-306,777
-37% -$8.33M 0.01% 1307
2024
Q3 		$28M Sell
825,117
-20,443
-2% -$779K 0.02% 799
2024
Q2 		$31.3M Buy
845,560
+272,389
+48% +$10.3M 0.03% 650
2024
Q1 		$24.1M Buy
573,171
+549,425
+2,314% +$22.6M 0.02% 822
2023
Q4 		$942K Sell
23,746
-13,038
-35% -$383K ﹤0.01% 3174
2023
Q3 		$1.01M Buy
36,784
+7,700
+26% +$241K ﹤0.01% 3048
2023
Q2 		$987K Buy
29,084
+2,534
+10% +$85.4K ﹤0.01% 3097
2023
Q1 		$955K Sell
26,550
-3,954
-13% -$171K ﹤0.01% 3198
2022
Q4 		$1.36M Sell
30,504
-78,161
-72% -$2.79M ﹤0.01% 3233
2022
Q3 		$3.06M Sell
108,665
-33,055
-23% -$1.01M ﹤0.01% 2624
2022
Q2 		$3.82M Buy
141,720
+19,548
+16% +$568K ﹤0.01% 2460
2022
Q1 		$4.16M Sell
122,172
-52,613
-30% -$1.68M ﹤0.01% 2531
2021
Q4 		$6.75M Buy
174,785
+60,861
+53% +$2.65M 0.01% 2066
2021
Q3 		$6.15M Buy
113,924
+83,625
+276% +$3.92M 0.01% 1916
2021
Q2 		$1.01M Buy
+30,299
New +$832K ﹤0.01% 3522
2019
Q4 		– Sell
-16,719
Closed -$36K – 3979
2019
Q3 		$36K Sell
16,719
-2,900
-15% -$6.71K ﹤0.01% 3742
2019
Q2 		$53K Sell
19,619
-86,062
-81% -$292K ﹤0.01% 3584
2019
Q1 		$520K Buy
105,681
+100,792
+2,062% +$530K ﹤0.01% 2990
2018
Q4 		$15K Sell
4,889
-15,579
-76% -$76.5K ﹤0.01% 3709
2018
Q3 		$138K Sell
20,468
-1,159
-5% -$8.11K ﹤0.01% 3596
2018
Q2 		$163K Sell
21,627
-1,439
-6% -$19.2K ﹤0.01% 3579
2018
Q1 		$806K Buy
23,066
+5,217
+29% +$202K ﹤0.01% 2635
2017
Q4 		$761K Buy
17,849
+10,702
+150% +$458K ﹤0.01% 2737
2017
Q3 		$306K Buy
7,147
+5,910
+478% +$222K ﹤0.01% 3134
2017
Q2 		$46K Sell
1,237
-2,696
-69% -$119K ﹤0.01% 3312
2017
Q1 		$213K Sell
3,933
-33,750
-90% -$1.76M ﹤0.01% 3099
2016
Q4 		$2M Sell
37,683
-36,679
-49% -$2.09M ﹤0.01% 2006
2016
Q3 		$4.51M Buy
74,362
+69,933
+1,579% +$4.36M 0.01% 1361
2016
Q2 		$292K Buy
+4,429
New +$281K ﹤0.01% 3027
2016
Q1 		– Sell
-6,281
Closed -$1.48M – 3455
2015
Q4 		$1.48M Buy
+6,281
New +$1.37M ﹤0.01% 2362
2015
Q3 		– Sell
-4,646
Closed -$1.76M – 3738
2015
Q2 		$1.76M Sell
4,646
-2,471
-35% -$981K ﹤0.01% 2288
2015
Q1 		$2.98M Sell
7,117
-3,395
-32% -$1.21M ﹤0.01% 1738
2014
Q4 		$2.88M Buy
10,512
+3,763
+56% +$936K ﹤0.01% 1965
2014
Q3 		$1.31M Buy
6,749
+3,234
+92% +$705K ﹤0.01% 2584
2014
Q2 		$860K Buy
3,515
+521
+17% +$118K ﹤0.01% 3072
2014
Q1 		$794K Sell
2,994
-2,143
-42% -$821K ﹤0.01% 3233
2013
Q4 		$1.87M Buy
5,137
+3,424
+200% +$1.32M ﹤0.01% 2590
2013
Q3 		$911K Sell
1,713
-2,163
-56% -$742K ﹤0.01% 3129
2013
Q2 		$908K Buy
+3,876
New +$763K ﹤0.01% 2796

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

D.E. Shaw & Co's CLDX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Celldex Therapeutics (CLDX) stake by 61% in Q1 2026, selling an estimated $2.28M and leaving 52,860 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #3048.

D.E. Shaw & Co first reported a position in CLDX in Q2 2013 and has held it in 44 quarters since. The position peaked at $31.3M in Q2 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • D.E. Shaw & Co held 52,860 shares of Celldex Therapeutics worth $1.68M as of Q1 2026.
  • D.E. Shaw & Co sold 83,464 Celldex Therapeutics shares in Q1 2026, an estimated $2.28M.
  • Celldex Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3048 holding.
  • D.E. Shaw & Co first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 44 quarters since.
  • D.E. Shaw & Co's Celldex Therapeutics position peaked at $31.3M in Q2 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.